Cardiovascular Disease Epidemiology

Cardiovascular disease (CVD) is the single largest killer in India and worldwide, and Community Medicine tests it relentlessly through the lens of risk factors, levels of prevention, the Geoffrey Rose population strategy, and hypertension classification. This topic sits at the crossroads of epidemiology, biostatistics, and the national NCD programme — master the framework once and you answer a whole cluster of NEET PG questions.

Definition & scope

Cardiovascular diseases are a group of disorders of the heart and blood vessels, the most important being:

• Coronary (ischaemic) heart disease (CHD/IHD) — angina, myocardial infarction, sudden cardiac death.
• Cerebrovascular disease — stroke (ischaemic and haemorrhagic).
• Hypertensive heart disease.
• Rheumatic heart disease (RHD) — still hugely relevant in India.
• Peripheral arterial disease, congenital heart disease, cardiomyopathies, deep vein thrombosis and pulmonary embolism.

Most adult atherosclerotic CVD shares a common multifactorial causation, which is why it is studied as a single epidemiological entity dominated by atherosclerosis as the underlying pathology.

High-yield: CVD is the leading cause of death globally (≈ 17.9 million deaths/year, ~32% of all global deaths, WHO). Over three-quarters of CVD deaths occur in low- and middle-income countries (LMICs) including India.

India's CVD burden — the "epidemiological transition"

India is in an advanced phase of epidemiological/health transition, where the disease burden is shifting from communicable, maternal and nutritional diseases towards non-communicable diseases (NCDs).

• CVDs account for roughly one-fourth to one-third of all deaths in India.
• Indians develop CHD about a decade earlier than Western populations, and at lower BMI/waist thresholds ("thin–fat Indian", high visceral adiposity, insulin resistance, low HDL, high Lp(a)).
• Rural areas now also show rising CVD — it is no longer a "disease of affluence" only.

High-yield: The earlier onset, higher case-fatality, and the so-called "Asian Indian phenotype" (central obesity + atherogenic dyslipidaemia + insulin resistance) are favourite single-best-answer points.

Risk factors — modifiable vs non-modifiable

This classification is the most tested table in the entire topic. Memorise which side each factor falls on.

Non-modifiable	Modifiable (behavioural & metabolic)
Age (risk rises with age)	Tobacco / smoking
Sex (male > pre-menopausal female)	Hypertension
Family history / genetics	Diabetes mellitus
Ethnicity (South Asians ↑)	Dyslipidaemia (↑LDL, ↑TG, ↓HDL)
	Obesity, esp. central obesity
	Physical inactivity / sedentary life
	Unhealthy diet (high salt, trans-fat, low fruit-veg)
	Harmful alcohol use
	Psychosocial stress

High-yield: The four behavioural risk factors targeted by WHO global NCD action are tobacco use, unhealthy diet, physical inactivity, and harmful use of alcohol. These lead to the four key metabolic/intermediate risk factors: raised blood pressure, raised blood glucose, raised blood lipids, and overweight/obesity.

High-yield: Raised blood pressure (hypertension) is the leading single attributable risk factor for cardiovascular mortality globally and the most important risk factor for stroke. Smoking is the most important avoidable/modifiable cause overall.

Mnemonic for modifiable CVD risk factors — "SHHHADOP": Smoking, Hypertension, Hyperglycaemia (diabetes), Hyperlipidaemia, Alcohol, Diet (unhealthy), Obesity, Physical inactivity.

Newer / emerging risk markers

• Lipoprotein(a) — independently elevated and atherogenic in Indians.
• High-sensitivity CRP (hs-CRP) — inflammatory marker.
• Homocysteine, fibrinogen, small dense LDL.
• Apolipoprotein B / Apo A-1 ratio.

The Framingham Heart Study

The Framingham Heart Study (begun 1948, Framingham town, Massachusetts, USA) is the classic prospective cohort study that gave us the very concept of a "risk factor."

• Study design: longitudinal cohort study (prospective).
• It established the role of hypertension, raised cholesterol, smoking, diabetes, age and sex in CHD.
• Produced the Framingham Risk Score, used to estimate 10-year risk of coronary/cardiovascular events.

High-yield: Framingham = cohort study that coined the term risk factor; remember the year 1948 and that it gives a 10-year CVD risk estimate. WHO/ISH and ASCVD pooled-cohort equations are later refinements.

High-yield: Other landmark studies sometimes paired in MCQs: Seven Countries Study (Ancel Keys — diet/saturated fat & CHD across countries) and INTERHEART study (case–control; identified ~9 modifiable risk factors accounting for >90% of population-attributable MI risk, incl. ApoB/ApoA-1, smoking, diabetes, hypertension, abdominal obesity, psychosocial, diet, exercise, alcohol).

Pathophysiology in brief

Risk factors → endothelial dysfunction → LDL deposition & oxidation in intima → foam cell (lipid-laden macrophage) formation → fatty streak → fibrous atheromatous plaque → plaque rupture/erosion → thrombosis → arterial occlusion → ischaemia/infarction.

Hypertension additionally causes left ventricular hypertrophy → heart failure, and accelerates atherosclerosis and aneurysm/dissection risk.

Geoffrey Rose — high-risk vs population (mass) strategy

This is the most frequently asked conceptual area in CVD epidemiology. Geoffrey Rose distinguished two complementary prevention approaches.

Feature	High-risk strategy	Population (mass) strategy
Target	Individuals in the top tail of risk distribution	The whole population; shift mean risk
Approach	Screen, identify high-risk, treat them	Small downward shift in entire distribution
Benefit to individual	Large (well motivated)	Small per person
Benefit to population	Often small	Often large
Cost-effectiveness	Good for the individual; labelling, medicalisation	Good for population; needs policy/structural change
Example	Treating people with BP >160/100	Reducing salt in all packaged food

High-yield (the "Prevention Paradox"): A preventive measure that brings large benefits to the community offers little to each participating individual. This is Geoffrey Rose's Prevention Paradox, and it is the single most quoted line from this topic. It justifies the population/mass strategy — because a large number of people at small risk give rise to more cases than the small number at high risk.

Flow of reasoning: Most cases of CVD arise from the large middle of the risk distribution, not the small extreme high-risk tail → therefore screening only high-risk individuals misses most future cases → shifting the whole population's mean (e.g., lowering everyone's BP/salt/cholesterol slightly) prevents more events overall.

Levels of prevention applied to CVD

Community Medicine loves matching an intervention to its level. Note that primordial prevention is the newest and most CVD-associated concept.

Level	Aim	CVD example
Primordial	Prevent emergence/establishment of risk factors in populations who don't yet have them	National policy to prevent tobacco initiation in children; promoting healthy lifestyle from childhood; reducing trans-fats in food supply
Primary	Prevent disease onset in those who already have risk factors	Smoking cessation, BP/lipid/glucose control, diet & exercise advice, salt reduction
Secondary	Early detection & treatment to halt progression	Screening for hypertension/diabetes; treating angina/post-MI to prevent reinfarction
Tertiary	Limit disability, rehabilitate	Cardiac rehabilitation, post-MI/post-stroke physiotherapy, surgery

High-yield: Primordial prevention = preventing the risk factor itself from appearing (the population has not yet acquired the risk factor). The classic example is preventing children/adolescents from taking up smoking or maintaining healthy dietary habits at a population level. This is distinct from primary prevention, which acts once risk factors exist.

High-yield: Health promotion + specific protection = primary prevention. Early diagnosis & treatment + disability limitation = secondary prevention boundary differs; rehabilitation = tertiary.

Hypertension classification — JNC and newer criteria

Hypertension is the most exam-relevant quantitative part of this topic. Know the JNC-7 categories (still asked) and the 2017 ACC/AHA lower cut-offs.

JNC-7 (2003) classification

Category	Systolic (mmHg)		Diastolic (mmHg)
Normal	< 120	and	< 80
Prehypertension	120–139	or	80–89
Stage 1 hypertension	140–159	or	90–99
Stage 2 hypertension	≥ 160	or	≥ 100

2017 ACC/AHA classification (newer, lower thresholds)

Category	Systolic (mmHg)		Diastolic (mmHg)
Normal	< 120	and	< 80
Elevated	120–129	and	< 80
Stage 1 HTN	130–139	or	80–89
Stage 2 HTN	≥ 140	or	≥ 90

High-yield: Under JNC-7, hypertension begins at ≥140/90; under 2017 ACC/AHA, Stage 1 begins at ≥130/80. When a question simply says "diagnostic cut-off for hypertension," the traditional 140/90 is the safest answer unless ACC/AHA is specified.

High-yield: Diagnosis requires ≥2 readings on ≥2 separate occasions (not a single elevated reading). Isolated systolic hypertension = SBP ≥140 with DBP <90, common in the elderly due to arterial stiffness.

Named entities to remember: JNC = Joint National Committee; the latest US guideline is the 2017 ACC/AHA; WHO/ISH also publishes guidance; ESC/ESH (European) use ≥140/90 with grades 1–3.

India's NCD response — NPCDCS / NP-NCD

The flagship programme is the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), launched 2010, now reorganised under the broader National Programme for Prevention & Control of Non-Communicable Diseases (NP-NCD).

Key features for MCQs:

• Operates through NCD clinics at CHC and district hospital level; integrated with Health & Wellness Centres (Ayushman Bharat) for population-based screening.
• Population-Based Screening (PBS) under Ayushman Bharat–HWC: opportunistic + community screening of all individuals aged ≥30 years for hypertension, diabetes, and three common cancers (oral, breast, cervical).
• Uses the CBAC form (Community-Based Assessment Checklist) to identify those at risk.
• Aligns with WHO "best buys" and the PEN (Package of Essential NCD interventions) for primary care.

High-yield: Under Ayushman Bharat HWC population-based screening, the target age for screening of hypertension & diabetes is ≥30 years, recorded using the CBAC form.

High-yield: Global target — WHO's "25 by 25" (later SDG 3.4) aimed for a 25% relative reduction in premature NCD mortality. SDG 3.4 target: one-third reduction in premature NCD mortality (ages 30–70) by 2030.

WHO "best buys" / population CVD interventions (mass strategy in action)

• Tobacco control (taxation, smoke-free laws, warnings) — most cost-effective.
• Salt/sodium reduction in the food supply.
• Elimination of industrial trans-fats.
• Restricting harmful alcohol use.
• Promotion of physical activity and healthy diet.
• Multidrug therapy (incl. aspirin/statin/antihypertensive) for those at high CVD risk.

Diagnosis & investigations (epidemiology angle)

• Blood pressure measurement — standardised technique, mean of repeated readings; mercury/validated digital sphygmomanometer; correct cuff size.
• Lipid profile — fasting; total cholesterol, LDL, HDL, triglycerides.
• Fasting/random plasma glucose, HbA1c for diabetes screening.
• ECG — LVH, ischaemia, prior MI.
• Risk scoring — Framingham, WHO/ISH risk charts, ASCVD pooled-cohort equation to estimate 10-year risk and decide statin/antihypertensive therapy.
• Anthropometry — BMI, waist circumference (Asian Indian cut-offs: ≥90 cm men, ≥80 cm women) and waist–hip ratio for central obesity.

High-yield: For CVD risk stratification in primary care, WHO/ISH risk prediction charts (by region, using age, sex, smoking, SBP, diabetes, total cholesterol) are the tool used in low-resource settings — they may be used without lab tests in the simplified version.

Management / preventive "drug of choice" pointers

While Community Medicine focuses on prevention, a few therapeutic one-liners recur:

• Lifestyle modification first (DASH diet, salt <5 g/day, weight loss, exercise ≥150 min/week moderate activity, tobacco cessation, alcohol moderation).
• Statins = drug of choice for lipid lowering / secondary prevention.
• Antihypertensives — thiazides, ACE inhibitors/ARBs, calcium-channel blockers, per indication.
• Aspirin for secondary prevention post-MI/stroke (not routine primary prevention now).
• Secondary prophylaxis of RHD — benzathine penicillin IM every 3 weeks.

High-yield: DASH (Dietary Approaches to Stop Hypertension) diet emphasises fruits, vegetables, low-fat dairy, whole grains, and low sodium — a model "population diet." WHO recommends salt intake <5 g/day (≈2 g sodium).

Complications

• Acute myocardial infarction, heart failure, arrhythmias, sudden cardiac death.
• Stroke (the major hypertension complication) and vascular dementia.
• Chronic kidney disease, hypertensive retinopathy, aortic aneurysm/dissection.
• Peripheral arterial disease, limb ischaemia.
• Economic complication: catastrophic health expenditure and loss of productive (30–70 yr) life years (high DALYs).

Key differentials / distinctions tested

• Primordial vs primary prevention — risk factor not yet present vs already present.
• High-risk vs population strategy — and the Prevention Paradox.
• Cohort (Framingham) vs case–control (INTERHEART) study designs.
• Modifiable vs non-modifiable risk factors (don't put age/sex/family history on the modifiable side).
• Attributable risk vs relative risk — for population impact use Population Attributable Risk (PAR); for individual causation use relative risk.

Recently asked / exam angle

• Geoffrey Rose's Prevention Paradox and the rationale for the population (mass) strategy vs high-risk strategy — repeatedly framed as "which strategy gives more population benefit?"
• Primordial prevention example — "preventing children from starting smoking" / "national lifestyle policy" is primordial, NOT primary.
• Identify the non-modifiable risk factor from a clinical vignette (answer is usually age, sex, or family history).
• JNC-7 vs 2017 ACC/AHA cut-offs — "Stage 1 HTN per ACC/AHA = ?" → 130–139/80–89.
• Framingham study design → prospective cohort; gives 10-year risk.
• NPCDCS screening age → ≥30 years, CBAC form.
• Single most important modifiable risk factor for stroke → hypertension.
• WHO most cost-effective ("best buy") intervention → tobacco taxation/control.
• Asian Indian phenotype / lower waist cut-offs (90 cm men, 80 cm women).

Rapid revision

1. CVD = No. 1 killer worldwide; ~17.9 million deaths/yr; >75% in LMICs.
2. Framingham Heart Study (1948) = prospective cohort, coined "risk factor", gives 10-year CVD risk.
3. INTERHEART = case–control; ~9 modifiable factors explain >90% of MI risk.
4. Non-modifiable = age, sex, family history, ethnicity; everything else is modifiable.
5. Hypertension = leading attributable risk factor for CV death and No. 1 risk for stroke.
6. Smoking = most important avoidable CVD risk factor; WHO best buy = tobacco control.
7. Prevention Paradox (Rose): community gains big, individual gains little → favours population/mass strategy.
8. Primordial prevention = stop the risk factor from ever appearing (e.g., kids never start smoking).
9. JNC-7: HTN ≥140/90; prehypertension 120–139/80–89. 2017 ACC/AHA: Stage 1 ≥130/80.
10. Diagnose HTN on ≥2 readings, ≥2 visits; isolated systolic HTN common in elderly.
11. NPCDCS (2010) / NP-NCD; HWC population screening of ≥30 yr using CBAC form; salt <5 g/day.
12. Asian Indian phenotype: central obesity (waist ≥90 cm men, ≥80 cm women), early-onset CHD, low HDL, high Lp(a); SDG 3.4 = 1/3 cut in premature NCD deaths by 2030.